Last reviewed · How we verify
Rabies vaccines + Rabies immunoglobulins
Rabies vaccines + Rabies immunoglobulins is a Vaccine + Immunoglobulin combination Biologic drug developed by Novartis. It is currently in Phase 3 development for Post-exposure prophylaxis of rabies virus infection, Pre-exposure prophylaxis in high-risk populations.
Rabies vaccines stimulate immune response against rabies virus, while rabies immunoglobulins provide immediate passive immunity through pre-formed antibodies.
Rabies vaccines stimulate immune response against rabies virus, while rabies immunoglobulins provide immediate passive immunity through pre-formed antibodies. Used for Post-exposure prophylaxis of rabies virus infection, Pre-exposure prophylaxis in high-risk populations.
At a glance
| Generic name | Rabies vaccines + Rabies immunoglobulins |
|---|---|
| Sponsor | Novartis |
| Drug class | Vaccine + Immunoglobulin combination |
| Target | Rabies virus glycoprotein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Rabies vaccines contain inactivated or attenuated rabies virus antigens that trigger active humoral and cellular immune responses, generating long-lasting antibodies and memory cells. Rabies immunoglobulins (RIG) provide rapid passive immunity by delivering pre-formed anti-rabies antibodies that neutralize virus before active immunity develops, critical in post-exposure prophylaxis where the incubation period is short.
Approved indications
- Post-exposure prophylaxis of rabies virus infection
- Pre-exposure prophylaxis in high-risk populations
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Headache
- Myalgia
- Fever
- Nausea
- Allergic reactions
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (PHASE2)
- Washington University WU 409: Immune Responses to Rabies Vaccine. (EARLY_PHASE1)
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (PHASE2)
- SYN023 With Rabies Vaccine in Healthy Pediatric Subjects (PHASE1)
- Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine (PHASE2)
- A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (PHASE1, PHASE2)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabies vaccines + Rabies immunoglobulins CI brief — competitive landscape report
- Rabies vaccines + Rabies immunoglobulins updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Rabies vaccines + Rabies immunoglobulins
What is Rabies vaccines + Rabies immunoglobulins?
How does Rabies vaccines + Rabies immunoglobulins work?
What is Rabies vaccines + Rabies immunoglobulins used for?
Who makes Rabies vaccines + Rabies immunoglobulins?
What drug class is Rabies vaccines + Rabies immunoglobulins in?
What development phase is Rabies vaccines + Rabies immunoglobulins in?
What are the side effects of Rabies vaccines + Rabies immunoglobulins?
What does Rabies vaccines + Rabies immunoglobulins target?
Related
- Drug class: All Vaccine + Immunoglobulin combination drugs
- Target: All drugs targeting Rabies virus glycoprotein
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Immunology
- Indication: Drugs for Post-exposure prophylaxis of rabies virus infection
- Indication: Drugs for Pre-exposure prophylaxis in high-risk populations
- Compare: Rabies vaccines + Rabies immunoglobulins vs similar drugs
- Pricing: Rabies vaccines + Rabies immunoglobulins cost, discount & access